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ACK OF INTRAMYOCARDIAL REPERFUS ION after successful coronary recanalization
as been deﬁned as the “no-reﬂow” phenomenon. The phenomenon is not uncommon (39% with
yocardial contrast echocardiography [MCE] and 43% using myocardial blush grade at coronary
ngiography) in humans after successful primary percutaneous coronary intervention (PCI) in the
etting of acute myocardial infarction (AMI). Ischemia, reperfusion, and atheroembolism are the 3 major
layers in the pathogenesis of no-reﬂow, mediating microvascular obstruction through endothelial
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Figure 1. Visual Appearance of Microvascular Obstruction
Visual appearance of microvascular obstruction (no-reﬂow) as black area (between arrows) at myocardial contrast echocardiography (MCE)
(A1) (also see Online Video 1) and cardiac magnetic resonance (B1) as compared to what a normal study would look like (A2 and B2).
MCE score index, a semiquantitative parameter of no-reﬂow, is a better predictor of left ventricular remodeling compared to end-diastolic
volume at baseline, peak creatine kinase, presence of collaterals, and symptom-to-balloon time. Patients with successful primary percuta-
neous coronary intervention with residual microvascular obstruction have an almost 50% worse event-free survival than those without
microvascular obstruction (with MCE [C] or with magnetic resonance imaging [D]).
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Focus on No-Reflow
86amage, tissue edema, platelet/ﬁbrin/leukocyte plugs, and free radical injury. MCE and contrast-
nhanced cardiac magnetic resonance (CMR) are the most common techniques for its diagnosis. The
ole for MCE is summarized in Figures 1 to 3. MCE can clearly delineate no reﬂow after primary PCI and
elps in prognostication. MCE can be used to test if treating no reﬂow will be useful in humans.
Figure 2. No-Reﬂow Can Be Sustained or Reversible
No-reﬂow area (between arrows) present at myocardial contrast echocardiography (MCE) performed 24 h after primary percutaneous coronary intervention (PCI)
(A) (see Online Video 1) is conﬁrmed with a similar extent at 1-month follow-up (B). In comparison, no-reﬂow area (between arrows) present at MCE performed
24 h after primary PCI (C) is signiﬁcantly reduced at 1-month follow-up (D). No-reﬂow has been shown to be reversible at 1 month in 50% of patients with no-
reﬂow at 24 h. No reﬂow on MCE inﬂuences left ventricular (LV) remodeling (end-diastolic [E] and end-systolic [F] LV volumes) in patients treated with primary
PCI. In patients with reﬂow, as assessed by MCE, volumes are unchanged at 1-month follow-up. On the other hand, patients with sustained no-reﬂow demon-
strate a progressive LV dilation. More importantly, patients with reversible no-reﬂow demonstrate preserved LV volumes.
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Figure 3. Plasma Levels of Endothelin-1 in a Patient With No-Reﬂow
In humans, plasma levels of endothelin 1 are higher in patients with no-reﬂow. In a canine model of ischemia-reperfusion, intracoronary administration of an
endothelin-A selective antagonist (LU135252) signiﬁcantly reduces both no-reﬂow and infarct size (A). We have recently found that the atheroembolic compo-
nent of no-reﬂow may be attenuated by mechanical interventions such as thrombus-aspiration at the time of PCI. Extent of no-reﬂow at MCE was signiﬁcantly
reduced in patients randomized to the thrombus-aspiration (group B) compared with the control (group A). Such beneﬁcial effect demonstrated at 24 h was
maintained at 1 week and 6 months (B). Abbreviations as in Figure 2.
